Skip to main content
OpenTrials
Completed

NCT Number: NCT02199847

Evaluation of the Effects of Pharmaton Tablets on Mental Performance and Physical Fatigue in Nurses Working Night Shift

The general aim of this study is to assess the effects of Pharmaton® Caplets on mental performance and physical fatigue in nurses and nursing auxiliaries working night shifts

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male and female nurses and nursing auxiliaries working night shift
  • Age range: 20 to 45 inclusive
  • BMI range: 18-30
  • Negative pregnancy test for females
  • Subjects must be free of any clinically significant disease or condition that required a physician's care and/or was to interfere with study evaluation and procedures
  • Clinical laboratory tests within normal limits or, if out of normal range, clinically acceptable to the investigator
  • Negative urine drug screen for drugs at screening
  • Subjects must be willing to give informed consent prior to study enrolment and be able to adhere to restrictions and examination schedules

Exclusion criteria

  • Any serious disorder that may interfere with his/her participation to the trial and the evaluation of the safety of the test drug (e.g. liver and/or renal disease, hypervitaminosis A, psychic disorder, etc.) and/or treatment with chronic medication
  • Pre-treatment (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug that may influence the trial symptomatology and may interfere with evaluation of the safety of the test drug (e.g. vitamins and minerals supplementation)
  • Individuals drinking more than 40 g alcohol/day (glass of 12.5 cl of wine 10° = 12 g; glass of 4 cl of aperitif 42° = 17 g; glass of 25 cl of beer 3° = 7.5 g; glass of 25 cl of beer 6° = 15 g); Alcohol and drug abuse according to Diagnostic and Statistic Manual, Version IV (DSM-IV)
  • Individuals drinking more that 6 cups of coffee or tea/day
  • Individuals smoking more than 10 cigarettes/day
  • Female volunteers in child-bearing age not using adequate means of birth control (contraceptive pills, Intrauterine Device (IUD), sterilization)
  • Pregnancy and/or lactation
  • Relevant allergy or known hypersensitivity to the investigational product or its excipients
  • Individuals taking or having taken recently other vitamins and minerals supplementation
  • Individuals with a current disorder likely to modify EEG recordings and/or computerized cognitive testing
  • Individuals having a history of cancer
  • Participation in another clinical trial within the last 3 months prior to the start of the study and concurrent participation in another clinical trial
  • Individuals without health insurance

Treatment and study plan

Pharmaton® Caplets

Drug

Placebo

Drug

Primary outcomes

  1. Change from baseline in mental performance as measured by the completion of Cognitive Drug Research tasks (CDR tasks) combined with Electroencephalogram (EEG) (post-shift)

    Time frame: at day 77

Secondary outcomes

  1. Change in mental performance as measured by the completion of Cognitive Drug Research tasks (CDR tasks) combined with Electroencephalogram)

    Time frame: up to day 77

  2. Assessment of spontaneous Electroencephalogram (EEG) and event related potentials

    Time frame: up to day 77

  3. Assessment of Sleep-Electroencephalogram parameters

    Time frame: Day -1, Day 1, Day 77

  4. Evaluation of Quality of life scales

    Time frame: up to day 77

  5. Evaluation of Sleep by Visual Analogue Scale (VAS)

    Time frame: up to day 77

  6. Assessment of 24-hours holter Electrocardiogram (ECG)

    Time frame: Day -1, Day1, Day 77

  7. Assessment of urinary cortisol levels

    Time frame: Day -1, Day1, Day 77

  8. Number of patients with adverse events

    Time frame: up to 3 months

  9. Assessment of tolerability by investigator on a 4-point scale

    Time frame: at day 77

  10. Assessment of tolerability by subject on a 4-point scale

    Time frame: Day 41, Day 77

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

An Evaluation of the Effects of Pharmaton® Caplets Film-coated Tablets on Mental Performance and Physical Fatigue in Nurses Working Night Shifts: a Double-blind, Placebo Controlled Pilot Trial

Important dates

Study start
2000
Primary completion
2001
First posted
Jul 25, 2014
Registry last updated
Jul 25, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.